Displaying 461 - 470 of 516
The ACE Board of Trustees consists of leaders in the endocrine field who have been elected to serve the organization. Their guidance and dedication are invaluable to ACE and its members.
PresidentScott D. Isaacs, MD, FACP, FACE
President ElectDace L. Trence, MD, MACE
TreasurerLeslie S. Eldeiry, MD, ECNU, FACE
SecretaryKenneth E. Izuora, MD, MBA, FACE
Immediate Past PresidentSusan L. Samson, MD, PhD, FRCPC, FACE
morea
document.getElementById('autoclick').click();
more
Corporate AACE Partnership (CAP)
The Corporate AACE Partnership (CAP) is a collaborative program for industry and AACE to advance patient care. Thank you to the following companies for supporting our mission, members and patients.
Gold Sponsors
more
Lewis E. Braverman, MD, MACE, 89, passed away peacefully on Monday, June 10, 2019. He leaves his wife Mimi Braverman; his sons, William Braverman and Daniel Braverman; and his five grandchildren.
Dr. Braverman was an undergraduate at Harvard College and graduated from medical school at Johns Hopkins University in 1955. He completed an Internal Medicine Residency at Boston City Hospital and an Endocrinology Fellowship in the Thorndike Memorial Laboratory.
Dr. Braverman had a passion for mentoring fellows, students and junior faculty, and is remembered as a superb mentor to generations…
moreAACE Member Felicia Cosman, MD, professor of medicine at Columbia University, New York, discussed the current state of osteoporosis treatment in an interview at AACE’s 28th Annual Scientific & Clinical Congress.
moreAACE Member Roy Taylor, MD
, discussed the pathogenesis of hepatic insulin resistance in people with type 2 diabetes in an interview at AACE’s 28th Annual Scientific & Clinical Congress.
moreAmong patients on hemodialysis, trabecular bone score was helpful in predicting fracture risk, researchers reported during an oral presentation of the findings at AACE’s 28th Annual Scientific & Clinical Congress.
moreThe investigational agent relacorilant significantly improved excess cortisol in patients with endogenous hypercortisolism, researchers reported at the AACE 28th Annual Scientific & Clinical Congress.
moreThe investigational agent teprotumumab was effective for reducing proptosis associated with thyroid eye disease, according to late-breaking phase III data presented by Raymond Douglas, MD, PhD, of Cedars Sinai Medical Center in Los Angeles, and colleagues, at the AACE 28th Annual Scientific & Clinical Congress.
more
